Under the Paperwork Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10708312				
	Filing Date		2004-02-24				
	First Named Inventor Todd		L. DePue				
	Art Unit		1732				
	Examiner Name Lawre		ence Emile Lambelet				
	Attorney Docket Number		MASLIAC-29				

	U.S.PATENTS						Remove				
			Kind Code ¹					Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5582789		1996-12-10	Stein et al.						
	2	5562797		1996-10-08	Phelps						
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add		_	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		_	
Examiner Initial*	Cite No			Name of Patentee or Applicant Rele			es,Columns,Lines where evant Passages or Relevant res Appear				
If you wis	1 h to a	dd additional U.S. Pub	lished Ap	plication citatio	n information	please click the Ad	d button	Add	1		
				FOREIGN PA	TENT DOCUM	MENTS		Remove		_	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patente Applicant of cited Document	e or		or Relevant		
	1	10120268	DE	A1	2001-12-20	Lear Corporation		Abstract Pro	ovided	Г	
	2	19814956	DE	A1	1999-10-07	HeidelGmbH & Co				F	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708312		
iling Date		2004-02-24		
irst Named Inventor Todd		DePue		
Art Unit		1732		
xaminer Name	Lawre	ence Emile Lambelet		
Homey Docket Numb	nr.	MASI IAC 20		

If you wisl	h to a	dd add	ditional For	eign Pat	tent Doo	cumen	nt citatio	on info	rmation	please	click the Add	button	Add	i		
					NON-	-PATE	ENT LIT	TERA	TURE D	OCUM	ENTS		Remo	ve		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, (ity and/or country where published,										T5				
	1															
If you wisl	h to a	dd add	ditional nor	n-patent	literatur	re doc	ument (citatio	n inform	ation pl	ease click the	Add b	utton	Add		_
						E	XAMIN	IER SI	GNAT	JRE						
Examiner	Signa	ture									Date Conside	ered				
											nce with MPE ext communi				rough a	

1 See Kins Code of USFTO Planto Documents at year, <u>USFTO COD</u> or MEPD 910.4. ² Enter office that issued the cocurrent, by the two-letter code (WPD Standard 513.). ² The Japanese parted coverents, the relication to the year of the region of the Emperor must proceed the serial number of the papert document. ² Nicid of Cocurrent by the appropriate symbols as indicated on the document under WPD Standard 51.16 if goostile. ³ Applicant is to place a check mark here if English intraguage strategies an additional standard companies of the Cocurrent of the Cocu

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10708312		
Filing Date			2004-02-24		
First Named Inventor Todd I		Todd	L. DePue		
Art Unit			1732		
	Examiner Name	Lawre	ence Emile Lambelet		
	Attorney Docket Number		MASI IAC-29		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David W. Dorton/	Date (YYYY-MM-DD)	2007-06-25				
Name/Print	David W. Dorton	Registration Number	51625				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.